OWC Pharmaceutical Research Corp.: 10-Q filed 2016-11-14

Name: OWC Pharmaceutical Research Corp.: 10-Q filed 2016-11-14
Creator: OWC Pharmaceutical Research Corp.
License: https://creativecommons.org/licenses/by/4.0/

What OWC Pharmaceutical Research Corp. reported in its quarterly report filed 2016-11-14 (fiscal Q3 2016): 22 published measures, 56 facts as tagged in accession 0001295345-16-000753.

This filing

Form: 10-Q (quarterly report)
Filed: 2016-11-14
Fiscal period: fiscal Q3 2016
Accession: 0001295345-16-000753 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All OWC Pharmaceutical Research Corp. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2016-09-30	129,765	USD
At 2015-12-31	430,448	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2016-09-30	236,507	USD
At 2015-12-31	107,626	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2016-09-30	-106,742	USD
At 2015-12-31	322,822	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	-140,794	USD	92
2016-01-01 to 2016-09-30	-628,912	USD	274
2015-07-01 to 2015-09-30	-408,225	USD	92
2015-01-01 to 2015-09-30	-1,422,255	USD	273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2016-01-01 to 2016-09-30	-397,838	USD	274
2015-01-01 to 2015-09-30	-1,043,552	USD	273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Unit	Days
2016-07-01 to 2016-09-30	USD	92
2016-01-01 to 2016-09-30	USD	274
2015-07-01 to 2015-09-30	USD	92
2015-01-01 to 2015-09-30	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2016-01-01 to 2016-09-30	121,250	USD	274
2015-01-01 to 2015-09-30	114,000	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2016-01-01 to 2016-09-30	-1,860	USD	274
2015-01-01 to 2015-09-30	-3,179	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2016-09-30	-8,177,778	USD
At 2015-12-31	-7,548,866	USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2016-09-30	17,504	USD
At 2015-12-31	22,899	USD

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2016-09-30	112,261	USD
At 2015-12-31	407,549	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	-2,055	USD	92
2016-01-01 to 2016-09-30	-43,615	USD	274
2015-07-01 to 2015-09-30	0	USD	92
2015-01-01 to 2015-09-30	0	USD	273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2016-09-30	186,507	USD
At 2015-12-31	107,626	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	30,363	USD	92
2016-01-01 to 2016-09-30	102,182	USD	274
2015-07-01 to 2015-09-30	96,834	USD	92
2015-01-01 to 2015-09-30	286,774	USD	273

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2016-09-30	8,708,358	USD
At 2015-12-31	8,533,525	USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2016-09-30	692	USD
At 2015-12-31	-10,922	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2016-09-30	25,821	USD
At 2015-12-31	24,607	USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	-136,861	USD	92
2016-01-01 to 2016-09-30	-617,298	USD	274
2015-07-01 to 2015-09-30	-407,332	USD	92
2015-01-01 to 2015-09-30	-1,426,970	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	74,898	USD	92
2016-01-01 to 2016-09-30	380,920	USD	274
2015-07-01 to 2015-09-30	311,391	USD	92
2015-01-01 to 2015-09-30	1,135,481	USD	273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2016-01-01 to 2016-09-30	0	USD	274
2015-01-01 to 2015-09-30	114,000	USD	273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2016-01-01 to 2016-09-30	-421	USD	274
2015-01-01 to 2015-09-30	0	USD	273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2016-01-01 to 2016-09-30	-19,258	USD	274
2015-01-01 to 2015-09-30	28,020	USD	273

Inspect the source

Entity: OWC Pharmaceutical Research Corp. / CIK 0001431934
Captured: 2026-09-22 19:47 UTC
SEC response SHA-256: 5a62036473d89e622be102a608ba10aaa02db1a8778e5f34f9de1894da63b491

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001431934.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))